fda tirzepatide shortage update says years-long is resolved, will give limited leeway to compounders Lilly's Tirzepatide No Longer on
Description
On the other hand, Tirzepatide has been specifically engineered with a broader focus on weight management, making it a distinct option for individuals seeking treatment for obesity, with or without diabetes
Neither should be ignored
GGT: Normal is 0-45 U/L for women, 0-65 U/L for men
Canada: The Canadian patent (CA 2,675,150) expires December 2028, with no patent term extension granted
Similarly, in the SYNERGY-NASH study (Table 3), improvement of at least one fibrosis stage without worsening of MASH was almost doubled with tirzepatide treatment than with placebo [5]
